Diseases /
Acute Lymphoblastic Leukemia
Back to Diseases List
Associated Genetic Biomarkers
Overview
NCI Definition: Leukemia with an acute onset, characterized by the presence of lymphoblasts in the bone marrow and the peripheral blood. It includes the acute B lymphoblastic leukemia and acute T lymphoblastic leukemia. [1]
Biomarker-Directed Therapies
Of the biomarker-directed therapies for acute lymphoblastic leukemia, 3 are FDA-approved in at least one setting and 5 have NCCN guidelines in at least one setting [3].
Blinatumomab +
Disease is predicted to be sensitive: -
|
Biomarker Criteria:
Sample must not match any of the following:
|
Clinical Setting(s): Refractory (NICE, SMC), Relapse (NICE, SMC) |
| Note: Blinatumomab is a bispecific CD19-directed CD3 T-cell engager indicated for the treatment of Philadelphia chromosome-negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). |
Bosutinib +
Disease is predicted to be sensitive: -
|
Biomarker Criteria:
Sample must match all of the following:
|
Clinical Setting(s): Refractory (NCCN), Relapse (NCCN) |
Disease is predicted to be resistant: -
Dasatinib +
Disease is predicted to be sensitive: -
|
Biomarker Criteria:
Sample must match all of the following:
|
Clinical Setting(s): Refractory (FDA, NCCN), Relapse (NCCN), Treatment Induction (NCCN) |
| Note: Not recommended as a single agent for patients 40 years and older with Ph-positive ALL. |
Disease is predicted to be resistant: -
|
Biomarker Criteria:
Sample must match all of the following:
Sample must match one or more of the following: Sample must match all of the following: |
Clinical Setting(s): Refractory (NCCN) |
Imatinib +
Disease is predicted to be sensitive: -
Disease is predicted to be resistant: -
|
Biomarker Criteria:
Sample must match all of the following:
Sample must match one or more of the following: Sample must match all of the following: |
Clinical Setting(s): Refractory (NCCN) |
Nilotinib +
Disease is predicted to be sensitive: -
Disease is predicted to be resistant: -
Ponatinib +
Disease is predicted to be sensitive: -
|
Biomarker Criteria:
Sample must match all of the following:
|
Clinical Setting(s): Maintenance therapy (FDA, NCCN), Refractory (FDA, NCCN), Relapse (FDA, NCCN), Treatment Induction (FDA, NCCN) |
| Note: Indicated for T315I-positive Ph+ ALL. |
|
Biomarker Criteria:
Sample must match one or more of the following:
|
Clinical Setting(s): Maintenance therapy (FDA, NCCN), Refractory (FDA, NCCN), Relapse (FDA, NCCN), Treatment Induction (FDA, NCCN) |
| Note: Indicated for T315I-positive Ph+ ALL. |
|
Biomarker Criteria:
Sample must match one or more of the following:
|
Clinical Setting(s): Maintenance therapy (FDA, NCCN), Refractory (FDA, NCCN), Relapse (FDA, NCCN), Treatment Induction (FDA, NCCN) |
| Note: Indicated for Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) for whom no other kinase inhibitors are indicated. |
Clinical Trials
There are 245 clinical trials for acute lymphoblastic leukemia, of which 173 are open and 72 are completed or closed. Of the trials that contain acute lymphoblastic leukemia as an inclusion criterion, 3 are early phase 1 (2 open), 82 are phase 1 (51 open), 43 are phase 1/phase 2 (36 open), 84 are phase 2 (56 open), 4 are phase 2/phase 3 (4 open), 14 are phase 3 (12 open), 4 are phase 4 (4 open), and 11 are no phase specified (8 open).
BCR-ABL1, t(9;22)(q34;q11), and KMT2A are the most frequent gene inclusion criteria for acute lymphoblastic leukemia clinical trials [3].
Fludarabine, cyclophosphamide, and allogeneic hematopoietic stem cell transplantation are the most common interventions in acute lymphoblastic leukemia clinical trials.
Significant Genes in Acute Lymphoblastic Leukemia
ABL1 +
ABL1 is an inclusion eligibility criterion in 94 clinical trials for acute lymphoblastic leukemia, of which 61 are open and 33 are closed. Of the trials that contain ABL1 status and acute lymphoblastic leukemia as inclusion criteria, 2 are early phase 1 (1 open), 23 are phase 1 (11 open), 11 are phase 1/phase 2 (9 open), 44 are phase 2 (29 open), 2 are phase 2/phase 3 (2 open), 7 are phase 3 (6 open), 2 are phase 4 (2 open), and 3 are no phase specified (1 open) [3].
Ponatinib, bosutinib, dasatinib, imatinib, and nilotinib have evidence of efficacy in patients with ABL1 mutation in acute lymphoblastic leukemia [3].
ABL2 +
ABL2 is an inclusion eligibility criterion in 9 clinical trials for acute lymphoblastic leukemia, of which 8 are open and 1 is closed. Of the trials that contain ABL2 status and acute lymphoblastic leukemia as inclusion criteria, 2 are phase 1 (1 open), 2 are phase 1/phase 2 (2 open), 3 are phase 2 (3 open), 1 is phase 2/phase 3 (1 open), and 1 is phase 3 (1 open) [3].
AFF1 +
AFF1 is an inclusion eligibility criterion in 50 clinical trials for acute lymphoblastic leukemia, of which 30 are open and 20 are closed. Of the trials that contain AFF1 status and acute lymphoblastic leukemia as inclusion criteria, 1 is early phase 1 (0 open), 17 are phase 1 (9 open), 3 are phase 1/phase 2 (3 open), 22 are phase 2 (13 open), 1 is phase 2/phase 3 (1 open), 4 are phase 3 (3 open), 1 is phase 4 (1 open), and 1 is no phase specified (0 open) [3].
ASXL1 +
ASXL1 is an inclusion eligibility criterion in 9 clinical trials for acute lymphoblastic leukemia, of which 9 are open and 0 are closed. Of the trials that contain ASXL1 status and acute lymphoblastic leukemia as inclusion criteria, 1 is early phase 1 (1 open), 2 are phase 1 (2 open), and 6 are phase 2 (6 open) [3].
ATM +
ATM is an inclusion eligibility criterion in 1 clinical trial for acute lymphoblastic leukemia, of which 1 is open and 0 are closed. Of the trial that contains ATM status and acute lymphoblastic leukemia as inclusion criteria, 1 is phase 2 (1 open) [3].
BCL2 +
BCL2 is an inclusion eligibility criterion in 3 clinical trials for acute lymphoblastic leukemia, of which 3 are open and 0 are closed. Of the trials that contain BCL2 status and acute lymphoblastic leukemia as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 2 are phase 2 (2 open) [3].
BCL6 +
BCL6 is an inclusion eligibility criterion in 3 clinical trials for acute lymphoblastic leukemia, of which 3 are open and 0 are closed. Of the trials that contain BCL6 status and acute lymphoblastic leukemia as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 2 are phase 2 (2 open) [3].
BCOR +
BCOR is an inclusion eligibility criterion in 1 clinical trial for acute lymphoblastic leukemia, of which 1 is open and 0 are closed. Of the trial that contains BCOR status and acute lymphoblastic leukemia as inclusion criteria, 1 is phase 2 (1 open) [3].
BCR +
BCR is an inclusion eligibility criterion in 92 clinical trials for acute lymphoblastic leukemia, of which 59 are open and 33 are closed. Of the trials that contain BCR status and acute lymphoblastic leukemia as inclusion criteria, 2 are early phase 1 (1 open), 23 are phase 1 (11 open), 10 are phase 1/phase 2 (8 open), 43 are phase 2 (28 open), 2 are phase 2/phase 3 (2 open), 7 are phase 3 (6 open), 2 are phase 4 (2 open), and 3 are no phase specified (1 open) [3].
Ponatinib, bosutinib, dasatinib, imatinib, and nilotinib have evidence of efficacy in patients with BCR mutation in acute lymphoblastic leukemia [3].
BIRC3 +
BIRC3 is an inclusion eligibility criterion in 1 clinical trial for acute lymphoblastic leukemia, of which 1 is open and 0 are closed. Of the trial that contains BIRC3 status and acute lymphoblastic leukemia as inclusion criteria, 1 is phase 2 (1 open) [3].
CBFA2T3 +
CBFA2T3 is an inclusion eligibility criterion in 1 clinical trial for acute lymphoblastic leukemia, of which 1 is open and 0 are closed. Of the trial that contains CBFA2T3 status and acute lymphoblastic leukemia as inclusion criteria, 1 is phase 2 (1 open) [3].
CBFB +
CBFB is an inclusion eligibility criterion in 13 clinical trials for acute lymphoblastic leukemia, of which 7 are open and 6 are closed. Of the trials that contain CBFB status and acute lymphoblastic leukemia as inclusion criteria, 6 are phase 1 (3 open), 1 is phase 1/phase 2 (1 open), 4 are phase 2 (2 open), 1 is phase 3 (1 open), and 1 is no phase specified (0 open) [3].
CEP72 +
CEP72 is an inclusion eligibility criterion in 1 clinical trial for acute lymphoblastic leukemia, of which 1 is open and 0 are closed. Of the trial that contains CEP72 status and acute lymphoblastic leukemia as inclusion criteria, 1 is phase 2/phase 3 (1 open) [3].
CREBBP +
CREBBP is an inclusion eligibility criterion in 2 clinical trials for acute lymphoblastic leukemia, of which 2 are open and 0 are closed. Of the trials that contain CREBBP status and acute lymphoblastic leukemia as inclusion criteria, 2 are phase 2 (2 open) [3].
CRLF2 +
CRLF2 is an inclusion eligibility criterion in 9 clinical trials for acute lymphoblastic leukemia, of which 8 are open and 1 is closed. Of the trials that contain CRLF2 status and acute lymphoblastic leukemia as inclusion criteria, 2 are phase 1 (1 open), 2 are phase 1/phase 2 (2 open), 3 are phase 2 (3 open), 1 is phase 2/phase 3 (1 open), and 1 is phase 3 (1 open) [3].
CSF1R +
CSF1R is an inclusion eligibility criterion in 2 clinical trials for acute lymphoblastic leukemia, of which 2 are open and 0 are closed. Of the trials that contain CSF1R status and acute lymphoblastic leukemia as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 3 (1 open) [3].
DEK +
DEK is an inclusion eligibility criterion in 42 clinical trials for acute lymphoblastic leukemia, of which 25 are open and 17 are closed. Of the trials that contain DEK status and acute lymphoblastic leukemia as inclusion criteria, 2 are early phase 1 (1 open), 14 are phase 1 (7 open), 3 are phase 1/phase 2 (3 open), 20 are phase 2 (12 open), 2 are phase 3 (2 open), and 1 is no phase specified (0 open) [3].
DNMT3A +
DNMT3A is an inclusion eligibility criterion in 1 clinical trial for acute lymphoblastic leukemia, of which 1 is open and 0 are closed. Of the trial that contains DNMT3A status and acute lymphoblastic leukemia as inclusion criteria, 1 is phase 1 (1 open) [3].
ELL +
ELL is an inclusion eligibility criterion in 36 clinical trials for acute lymphoblastic leukemia, of which 19 are open and 17 are closed. Of the trials that contain ELL status and acute lymphoblastic leukemia as inclusion criteria, 1 is early phase 1 (0 open), 15 are phase 1 (7 open), 2 are phase 1/phase 2 (2 open), 15 are phase 2 (8 open), 2 are phase 3 (2 open), and 1 is no phase specified (0 open) [3].
EPOR +
EPOR is an inclusion eligibility criterion in 9 clinical trials for acute lymphoblastic leukemia, of which 8 are open and 1 is closed. Of the trials that contain EPOR status and acute lymphoblastic leukemia as inclusion criteria, 2 are phase 1 (1 open), 2 are phase 1/phase 2 (2 open), 3 are phase 2 (3 open), 1 is phase 2/phase 3 (1 open), and 1 is phase 3 (1 open) [3].
ETV6 +
ETV6 is an inclusion eligibility criterion in 3 clinical trials for acute lymphoblastic leukemia, of which 3 are open and 0 are closed. Of the trials that contain ETV6 status and acute lymphoblastic leukemia as inclusion criteria, 1 is phase 1 (1 open) and 2 are phase 2 (2 open) [3].
FGFR1 +
FGFR1 is an inclusion eligibility criterion in 8 clinical trials for acute lymphoblastic leukemia, of which 7 are open and 1 is closed. Of the trials that contain FGFR1 status and acute lymphoblastic leukemia as inclusion criteria, 2 are phase 1 (1 open), 2 are phase 1/phase 2 (2 open), 3 are phase 2 (3 open), and 1 is phase 2/phase 3 (1 open) [3].
FGFR2 +
FGFR2 is an inclusion eligibility criterion in 8 clinical trials for acute lymphoblastic leukemia, of which 7 are open and 1 is closed. Of the trials that contain FGFR2 status and acute lymphoblastic leukemia as inclusion criteria, 2 are phase 1 (1 open), 2 are phase 1/phase 2 (2 open), 3 are phase 2 (3 open), and 1 is phase 2/phase 3 (1 open) [3].
FGFR3 +
FGFR3 is an inclusion eligibility criterion in 11 clinical trials for acute lymphoblastic leukemia, of which 9 are open and 2 are closed. Of the trials that contain FGFR3 status and acute lymphoblastic leukemia as inclusion criteria, 4 are phase 1 (2 open), 2 are phase 1/phase 2 (2 open), 4 are phase 2 (4 open), and 1 is phase 2/phase 3 (1 open) [3].
FGFR4 +
FGFR4 is an inclusion eligibility criterion in 8 clinical trials for acute lymphoblastic leukemia, of which 7 are open and 1 is closed. Of the trials that contain FGFR4 status and acute lymphoblastic leukemia as inclusion criteria, 2 are phase 1 (1 open), 2 are phase 1/phase 2 (2 open), 3 are phase 2 (3 open), and 1 is phase 2/phase 3 (1 open) [3].
FLT1 +
FLT1 is an inclusion eligibility criterion in 1 clinical trial for acute lymphoblastic leukemia, of which 1 is open and 0 are closed. Of the trial that contains FLT1 status and acute lymphoblastic leukemia as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].
FLT3 +
FLT3 is an inclusion eligibility criterion in 57 clinical trials for acute lymphoblastic leukemia, of which 33 are open and 24 are closed. Of the trials that contain FLT3 status and acute lymphoblastic leukemia as inclusion criteria, 2 are early phase 1 (1 open), 18 are phase 1 (9 open), 7 are phase 1/phase 2 (6 open), 25 are phase 2 (14 open), 1 is phase 2/phase 3 (1 open), 3 are phase 3 (2 open), and 1 is no phase specified (0 open) [3].
GLIS2 +
GLIS2 is an inclusion eligibility criterion in 1 clinical trial for acute lymphoblastic leukemia, of which 1 is open and 0 are closed. Of the trial that contains GLIS2 status and acute lymphoblastic leukemia as inclusion criteria, 1 is phase 2 (1 open) [3].
HIP1 +
HIP1 is an inclusion eligibility criterion in 1 clinical trial for acute lymphoblastic leukemia, of which 1 is open and 0 are closed. Of the trial that contains HIP1 status and acute lymphoblastic leukemia as inclusion criteria, 1 is phase 2 (1 open) [3].
HOXA9 +
HOXA9 is an inclusion eligibility criterion in 1 clinical trial for acute lymphoblastic leukemia, of which 1 is open and 0 are closed. Of the trial that contains HOXA9 status and acute lymphoblastic leukemia as inclusion criteria, 1 is phase 2 (1 open) [3].
HRAS +
HRAS is an inclusion eligibility criterion in 2 clinical trials for acute lymphoblastic leukemia, of which 2 are open and 0 are closed. Of the trials that contain HRAS status and acute lymphoblastic leukemia as inclusion criteria, 1 is early phase 1 (1 open) and 1 is phase 2 (1 open) [3].
IGH +
IGH is an inclusion eligibility criterion in 6 clinical trials for acute lymphoblastic leukemia, of which 4 are open and 2 are closed. Of the trials that contain IGH status and acute lymphoblastic leukemia as inclusion criteria, 2 are phase 1 (1 open), 1 is phase 1/phase 2 (1 open), and 3 are phase 2 (2 open) [3].
IKZF1 +
IKZF1 is an inclusion eligibility criterion in 3 clinical trials for acute lymphoblastic leukemia, of which 1 is open and 2 are closed. Of the trials that contain IKZF1 status and acute lymphoblastic leukemia as inclusion criteria, 3 are phase 2 (1 open) [3].
IL7R +
IL7R is an inclusion eligibility criterion in 8 clinical trials for acute lymphoblastic leukemia, of which 7 are open and 1 is closed. Of the trials that contain IL7R status and acute lymphoblastic leukemia as inclusion criteria, 2 are phase 1 (1 open), 2 are phase 1/phase 2 (2 open), 3 are phase 2 (3 open), and 1 is phase 2/phase 3 (1 open) [3].
JAK1 +
JAK1 is an inclusion eligibility criterion in 8 clinical trials for acute lymphoblastic leukemia, of which 7 are open and 1 is closed. Of the trials that contain JAK1 status and acute lymphoblastic leukemia as inclusion criteria, 2 are phase 1 (1 open), 2 are phase 1/phase 2 (2 open), 3 are phase 2 (3 open), and 1 is phase 2/phase 3 (1 open) [3].
JAK2 +
JAK2 is an inclusion eligibility criterion in 10 clinical trials for acute lymphoblastic leukemia, of which 9 are open and 1 is closed. Of the trials that contain JAK2 status and acute lymphoblastic leukemia as inclusion criteria, 1 is early phase 1 (1 open), 2 are phase 1 (1 open), 2 are phase 1/phase 2 (2 open), 3 are phase 2 (3 open), 1 is phase 2/phase 3 (1 open), and 1 is phase 3 (1 open) [3].
JAK3 +
JAK3 is an inclusion eligibility criterion in 8 clinical trials for acute lymphoblastic leukemia, of which 7 are open and 1 is closed. Of the trials that contain JAK3 status and acute lymphoblastic leukemia as inclusion criteria, 2 are phase 1 (1 open), 2 are phase 1/phase 2 (2 open), 3 are phase 2 (3 open), and 1 is phase 2/phase 3 (1 open) [3].
KAT6A +
KAT6A is an inclusion eligibility criterion in 1 clinical trial for acute lymphoblastic leukemia, of which 1 is open and 0 are closed. Of the trial that contains KAT6A status and acute lymphoblastic leukemia as inclusion criteria, 1 is phase 2 (1 open) [3].
KDM5A +
KDM5A is an inclusion eligibility criterion in 1 clinical trial for acute lymphoblastic leukemia, of which 1 is open and 0 are closed. Of the trial that contains KDM5A status and acute lymphoblastic leukemia as inclusion criteria, 1 is phase 2 (1 open) [3].
KIT +
KIT is an inclusion eligibility criterion in 14 clinical trials for acute lymphoblastic leukemia, of which 8 are open and 6 are closed. Of the trials that contain KIT status and acute lymphoblastic leukemia as inclusion criteria, 6 are phase 1 (3 open), 1 is phase 1/phase 2 (1 open), 5 are phase 2 (3 open), 1 is phase 3 (1 open), and 1 is no phase specified (0 open) [3].
KMT2A +
KMT2A is an inclusion eligibility criterion in 65 clinical trials for acute lymphoblastic leukemia, of which 41 are open and 24 are closed. Of the trials that contain KMT2A status and acute lymphoblastic leukemia as inclusion criteria, 2 are early phase 1 (1 open), 22 are phase 1 (12 open), 9 are phase 1/phase 2 (8 open), 24 are phase 2 (14 open), 1 is phase 2/phase 3 (1 open), 4 are phase 3 (3 open), 1 is phase 4 (1 open), and 2 are no phase specified (1 open) [3].
KRAS +
KRAS is an inclusion eligibility criterion in 3 clinical trials for acute lymphoblastic leukemia, of which 2 are open and 1 is closed. Of the trials that contain KRAS status and acute lymphoblastic leukemia as inclusion criteria, 1 is early phase 1 (1 open), 1 is phase 1/phase 2 (0 open), and 1 is phase 2 (1 open) [3].
LYN +
LYN is an inclusion eligibility criterion in 8 clinical trials for acute lymphoblastic leukemia, of which 7 are open and 1 is closed. Of the trials that contain LYN status and acute lymphoblastic leukemia as inclusion criteria, 2 are phase 1 (1 open), 2 are phase 1/phase 2 (2 open), 3 are phase 2 (3 open), and 1 is phase 2/phase 3 (1 open) [3].
MAF +
MAF is an inclusion eligibility criterion in 2 clinical trials for acute lymphoblastic leukemia, of which 2 are open and 0 are closed. Of the trials that contain MAF status and acute lymphoblastic leukemia as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [3].
MAFB +
MAFB is an inclusion eligibility criterion in 2 clinical trials for acute lymphoblastic leukemia, of which 2 are open and 0 are closed. Of the trials that contain MAFB status and acute lymphoblastic leukemia as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [3].
MDM2 +
MDM2 is an inclusion eligibility criterion in 1 clinical trial for acute lymphoblastic leukemia, of which 1 is open and 0 are closed. Of the trial that contains MDM2 status and acute lymphoblastic leukemia as inclusion criteria, 1 is phase 1 (1 open) [3].
MDM4 +
MDM4 is an inclusion eligibility criterion in 1 clinical trial for acute lymphoblastic leukemia, of which 1 is open and 0 are closed. Of the trial that contains MDM4 status and acute lymphoblastic leukemia as inclusion criteria, 1 is phase 1 (1 open) [3].
MECOM +
MECOM is an inclusion eligibility criterion in 56 clinical trials for acute lymphoblastic leukemia, of which 36 are open and 20 are closed. Of the trials that contain MECOM status and acute lymphoblastic leukemia as inclusion criteria, 2 are early phase 1 (1 open), 19 are phase 1 (10 open), 6 are phase 1/phase 2 (6 open), 25 are phase 2 (16 open), 1 is phase 2/phase 3 (1 open), 2 are phase 3 (2 open), and 1 is no phase specified (0 open) [3].
MLF1 +
MLF1 is an inclusion eligibility criterion in 24 clinical trials for acute lymphoblastic leukemia, of which 17 are open and 7 are closed. Of the trials that contain MLF1 status and acute lymphoblastic leukemia as inclusion criteria, 1 is early phase 1 (0 open), 7 are phase 1 (4 open), 3 are phase 1/phase 2 (3 open), 11 are phase 2 (8 open), 1 is phase 2/phase 3 (1 open), and 1 is phase 3 (1 open) [3].
MLLT1 +
MLLT1 is an inclusion eligibility criterion in 37 clinical trials for acute lymphoblastic leukemia, of which 19 are open and 18 are closed. Of the trials that contain MLLT1 status and acute lymphoblastic leukemia as inclusion criteria, 1 is early phase 1 (0 open), 15 are phase 1 (7 open), 2 are phase 1/phase 2 (2 open), 16 are phase 2 (8 open), 2 are phase 3 (2 open), and 1 is no phase specified (0 open) [3].
MLLT10 +
MLLT10 is an inclusion eligibility criterion in 36 clinical trials for acute lymphoblastic leukemia, of which 19 are open and 17 are closed. Of the trials that contain MLLT10 status and acute lymphoblastic leukemia as inclusion criteria, 1 is early phase 1 (0 open), 15 are phase 1 (7 open), 2 are phase 1/phase 2 (2 open), 15 are phase 2 (8 open), 2 are phase 3 (2 open), and 1 is no phase specified (0 open) [3].
MLLT3 +
MLLT3 is an inclusion eligibility criterion in 38 clinical trials for acute lymphoblastic leukemia, of which 21 are open and 17 are closed. Of the trials that contain MLLT3 status and acute lymphoblastic leukemia as inclusion criteria, 1 is early phase 1 (0 open), 16 are phase 1 (8 open), 2 are phase 1/phase 2 (2 open), 16 are phase 2 (9 open), 2 are phase 3 (2 open), and 1 is no phase specified (0 open) [3].
MLLT4 +
MLLT4 is an inclusion eligibility criterion in 37 clinical trials for acute lymphoblastic leukemia, of which 19 are open and 18 are closed. Of the trials that contain MLLT4 status and acute lymphoblastic leukemia as inclusion criteria, 1 is early phase 1 (0 open), 15 are phase 1 (7 open), 2 are phase 1/phase 2 (2 open), 16 are phase 2 (8 open), 2 are phase 3 (2 open), and 1 is no phase specified (0 open) [3].
MNX1 +
MNX1 is an inclusion eligibility criterion in 1 clinical trial for acute lymphoblastic leukemia, of which 1 is open and 0 are closed. Of the trial that contains MNX1 status and acute lymphoblastic leukemia as inclusion criteria, 1 is phase 2 (1 open) [3].
MYC +
MYC is an inclusion eligibility criterion in 5 clinical trials for acute lymphoblastic leukemia, of which 4 are open and 1 is closed. Of the trials that contain MYC status and acute lymphoblastic leukemia as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 4 are phase 2 (3 open) [3].
MYH11 +
MYH11 is an inclusion eligibility criterion in 13 clinical trials for acute lymphoblastic leukemia, of which 7 are open and 6 are closed. Of the trials that contain MYH11 status and acute lymphoblastic leukemia as inclusion criteria, 6 are phase 1 (3 open), 1 is phase 1/phase 2 (1 open), 4 are phase 2 (2 open), 1 is phase 3 (1 open), and 1 is no phase specified (0 open) [3].
NPM1 +
NPM1 is an inclusion eligibility criterion in 31 clinical trials for acute lymphoblastic leukemia, of which 23 are open and 8 are closed. Of the trials that contain NPM1 status and acute lymphoblastic leukemia as inclusion criteria, 1 is early phase 1 (0 open), 8 are phase 1 (5 open), 7 are phase 1/phase 2 (7 open), 13 are phase 2 (9 open), 1 is phase 2/phase 3 (1 open), and 1 is phase 3 (1 open) [3].
NRAS +
NRAS is an inclusion eligibility criterion in 3 clinical trials for acute lymphoblastic leukemia, of which 2 are open and 1 is closed. Of the trials that contain NRAS status and acute lymphoblastic leukemia as inclusion criteria, 1 is early phase 1 (1 open), 1 is phase 1/phase 2 (0 open), and 1 is phase 2 (1 open) [3].
NRIP3 +
NRIP3 is an inclusion eligibility criterion in 36 clinical trials for acute lymphoblastic leukemia, of which 19 are open and 17 are closed. Of the trials that contain NRIP3 status and acute lymphoblastic leukemia as inclusion criteria, 1 is early phase 1 (0 open), 15 are phase 1 (7 open), 2 are phase 1/phase 2 (2 open), 15 are phase 2 (8 open), 2 are phase 3 (2 open), and 1 is no phase specified (0 open) [3].
NSD1 +
NSD1 is an inclusion eligibility criterion in 1 clinical trial for acute lymphoblastic leukemia, of which 1 is open and 0 are closed. Of the trial that contains NSD1 status and acute lymphoblastic leukemia as inclusion criteria, 1 is phase 2 (1 open) [3].
NTRK1 +
NTRK1 is an inclusion eligibility criterion in 8 clinical trials for acute lymphoblastic leukemia, of which 7 are open and 1 is closed. Of the trials that contain NTRK1 status and acute lymphoblastic leukemia as inclusion criteria, 2 are phase 1 (1 open), 2 are phase 1/phase 2 (2 open), 3 are phase 2 (3 open), and 1 is phase 2/phase 3 (1 open) [3].
NTRK2 +
NTRK2 is an inclusion eligibility criterion in 8 clinical trials for acute lymphoblastic leukemia, of which 7 are open and 1 is closed. Of the trials that contain NTRK2 status and acute lymphoblastic leukemia as inclusion criteria, 2 are phase 1 (1 open), 2 are phase 1/phase 2 (2 open), 3 are phase 2 (3 open), and 1 is phase 2/phase 3 (1 open) [3].
NTRK3 +
NTRK3 is an inclusion eligibility criterion in 8 clinical trials for acute lymphoblastic leukemia, of which 7 are open and 1 is closed. Of the trials that contain NTRK3 status and acute lymphoblastic leukemia as inclusion criteria, 2 are phase 1 (1 open), 2 are phase 1/phase 2 (2 open), 3 are phase 2 (3 open), and 1 is phase 2/phase 3 (1 open) [3].
NUP214 +
NUP214 is an inclusion eligibility criterion in 42 clinical trials for acute lymphoblastic leukemia, of which 25 are open and 17 are closed. Of the trials that contain NUP214 status and acute lymphoblastic leukemia as inclusion criteria, 2 are early phase 1 (1 open), 14 are phase 1 (7 open), 3 are phase 1/phase 2 (3 open), 20 are phase 2 (12 open), 2 are phase 3 (2 open), and 1 is no phase specified (0 open) [3].
NUP98 +
NUP98 is an inclusion eligibility criterion in 1 clinical trial for acute lymphoblastic leukemia, of which 1 is open and 0 are closed. Of the trial that contains NUP98 status and acute lymphoblastic leukemia as inclusion criteria, 1 is phase 2 (1 open) [3].
PBX1 +
PBX1 is an inclusion eligibility criterion in 33 clinical trials for acute lymphoblastic leukemia, of which 22 are open and 11 are closed. Of the trials that contain PBX1 status and acute lymphoblastic leukemia as inclusion criteria, 1 is early phase 1 (0 open), 9 are phase 1 (5 open), 4 are phase 1/phase 2 (4 open), 16 are phase 2 (11 open), and 3 are phase 3 (2 open) [3].
PDGFRA +
PDGFRA is an inclusion eligibility criterion in 9 clinical trials for acute lymphoblastic leukemia, of which 8 are open and 1 is closed. Of the trials that contain PDGFRA status and acute lymphoblastic leukemia as inclusion criteria, 2 are phase 1 (1 open), 3 are phase 1/phase 2 (3 open), 3 are phase 2 (3 open), and 1 is phase 2/phase 3 (1 open) [3].
PDGFRB +
PDGFRB is an inclusion eligibility criterion in 10 clinical trials for acute lymphoblastic leukemia, of which 9 are open and 1 is closed. Of the trials that contain PDGFRB status and acute lymphoblastic leukemia as inclusion criteria, 2 are phase 1 (1 open), 2 are phase 1/phase 2 (2 open), 4 are phase 2 (4 open), 1 is phase 2/phase 3 (1 open), and 1 is phase 3 (1 open) [3].
PHF6 +
PHF6 is an inclusion eligibility criterion in 1 clinical trial for acute lymphoblastic leukemia, of which 1 is open and 0 are closed. Of the trial that contains PHF6 status and acute lymphoblastic leukemia as inclusion criteria, 1 is phase 1 (1 open) [3].
PML +
PML is an inclusion eligibility criterion in 2 clinical trials for acute lymphoblastic leukemia, of which 1 is open and 1 is closed. Of the trials that contain PML status and acute lymphoblastic leukemia as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (0 open) [3].
PPM1D +
PPM1D is an inclusion eligibility criterion in 1 clinical trial for acute lymphoblastic leukemia, of which 1 is open and 0 are closed. Of the trial that contains PPM1D status and acute lymphoblastic leukemia as inclusion criteria, 1 is phase 1 (1 open) [3].
PRDM16 +
PRDM16 is an inclusion eligibility criterion in 1 clinical trial for acute lymphoblastic leukemia, of which 1 is open and 0 are closed. Of the trial that contains PRDM16 status and acute lymphoblastic leukemia as inclusion criteria, 1 is phase 2 (1 open) [3].
RARA +
RARA is an inclusion eligibility criterion in 2 clinical trials for acute lymphoblastic leukemia, of which 1 is open and 1 is closed. Of the trials that contain RARA status and acute lymphoblastic leukemia as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (0 open) [3].
RET +
RET is an inclusion eligibility criterion in 1 clinical trial for acute lymphoblastic leukemia, of which 1 is open and 0 are closed. Of the trial that contains RET status and acute lymphoblastic leukemia as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].
RPN1 +
RPN1 is an inclusion eligibility criterion in 56 clinical trials for acute lymphoblastic leukemia, of which 36 are open and 20 are closed. Of the trials that contain RPN1 status and acute lymphoblastic leukemia as inclusion criteria, 2 are early phase 1 (1 open), 19 are phase 1 (10 open), 6 are phase 1/phase 2 (6 open), 25 are phase 2 (16 open), 1 is phase 2/phase 3 (1 open), 2 are phase 3 (2 open), and 1 is no phase specified (0 open) [3].
RUNX1 +
RUNX1 is an inclusion eligibility criterion in 22 clinical trials for acute lymphoblastic leukemia, of which 16 are open and 6 are closed. Of the trials that contain RUNX1 status and acute lymphoblastic leukemia as inclusion criteria, 1 is early phase 1 (1 open), 8 are phase 1 (5 open), 1 is phase 1/phase 2 (1 open), 10 are phase 2 (8 open), 1 is phase 3 (1 open), and 1 is no phase specified (0 open) [3].
RUNX1T1 +
RUNX1T1 is an inclusion eligibility criterion in 13 clinical trials for acute lymphoblastic leukemia, of which 7 are open and 6 are closed. Of the trials that contain RUNX1T1 status and acute lymphoblastic leukemia as inclusion criteria, 6 are phase 1 (3 open), 1 is phase 1/phase 2 (1 open), 4 are phase 2 (2 open), 1 is phase 3 (1 open), and 1 is no phase specified (0 open) [3].
SF3B1 +
SF3B1 is an inclusion eligibility criterion in 1 clinical trial for acute lymphoblastic leukemia, of which 1 is open and 0 are closed. Of the trial that contains SF3B1 status and acute lymphoblastic leukemia as inclusion criteria, 1 is phase 2 (1 open) [3].
SH2B3 +
SH2B3 is an inclusion eligibility criterion in 8 clinical trials for acute lymphoblastic leukemia, of which 7 are open and 1 is closed. Of the trials that contain SH2B3 status and acute lymphoblastic leukemia as inclusion criteria, 2 are phase 1 (1 open), 2 are phase 1/phase 2 (2 open), 3 are phase 2 (3 open), and 1 is phase 2/phase 3 (1 open) [3].
SMARCA4 +
SMARCA4 is an inclusion eligibility criterion in 1 clinical trial for acute lymphoblastic leukemia, of which 1 is open and 0 are closed. Of the trial that contains SMARCA4 status and acute lymphoblastic leukemia as inclusion criteria, 1 is phase 1 (1 open) [3].
SMARCB1 +
SMARCB1 is an inclusion eligibility criterion in 1 clinical trial for acute lymphoblastic leukemia, of which 1 is open and 0 are closed. Of the trial that contains SMARCB1 status and acute lymphoblastic leukemia as inclusion criteria, 1 is phase 1 (1 open) [3].
TCF3 +
TCF3 is an inclusion eligibility criterion in 33 clinical trials for acute lymphoblastic leukemia, of which 22 are open and 11 are closed. Of the trials that contain TCF3 status and acute lymphoblastic leukemia as inclusion criteria, 1 is early phase 1 (0 open), 9 are phase 1 (5 open), 4 are phase 1/phase 2 (4 open), 16 are phase 2 (11 open), and 3 are phase 3 (2 open) [3].
TET2 +
TET2 is an inclusion eligibility criterion in 2 clinical trials for acute lymphoblastic leukemia, of which 2 are open and 0 are closed. Of the trials that contain TET2 status and acute lymphoblastic leukemia as inclusion criteria, 2 are phase 1 (2 open) [3].
TP53 +
TP53 is an inclusion eligibility criterion in 41 clinical trials for acute lymphoblastic leukemia, of which 24 are open and 17 are closed. Of the trials that contain TP53 status and acute lymphoblastic leukemia as inclusion criteria, 2 are early phase 1 (1 open), 16 are phase 1 (8 open), 2 are phase 1/phase 2 (2 open), 18 are phase 2 (11 open), 2 are phase 3 (2 open), and 1 is no phase specified (0 open) [3].
TRA +
TRA is an inclusion eligibility criterion in 1 clinical trial for acute lymphoblastic leukemia, of which 1 is open and 0 are closed. Of the trial that contains TRA status and acute lymphoblastic leukemia as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].
TRB +
TRB is an inclusion eligibility criterion in 1 clinical trial for acute lymphoblastic leukemia, of which 1 is open and 0 are closed. Of the trial that contains TRB status and acute lymphoblastic leukemia as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].
TRD +
TRD is an inclusion eligibility criterion in 1 clinical trial for acute lymphoblastic leukemia, of which 1 is open and 0 are closed. Of the trial that contains TRD status and acute lymphoblastic leukemia as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].
TRG +
TRG is an inclusion eligibility criterion in 1 clinical trial for acute lymphoblastic leukemia, of which 1 is open and 0 are closed. Of the trial that contains TRG status and acute lymphoblastic leukemia as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].
TYK2 +
TYK2 is an inclusion eligibility criterion in 8 clinical trials for acute lymphoblastic leukemia, of which 7 are open and 1 is closed. Of the trials that contain TYK2 status and acute lymphoblastic leukemia as inclusion criteria, 2 are phase 1 (1 open), 2 are phase 1/phase 2 (2 open), 3 are phase 2 (3 open), and 1 is phase 2/phase 3 (1 open) [3].
WHSC1 +
WHSC1 is an inclusion eligibility criterion in 2 clinical trials for acute lymphoblastic leukemia, of which 2 are open and 0 are closed. Of the trials that contain WHSC1 status and acute lymphoblastic leukemia as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [3].
WT1 +
WT1 is an inclusion eligibility criterion in 1 clinical trial for acute lymphoblastic leukemia, of which 1 is open and 0 are closed. Of the trial that contains WT1 status and acute lymphoblastic leukemia as inclusion criteria, 1 is phase 2 (1 open) [3].
Disease Details
References
1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/ [2018-08-28]. [2018-09-21].
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.
3. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.
